Compare Incyte Corporation (INCY) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Value Index Fund ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Vanguard Value Index Fund ETF trades at $220.59 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 11.5× Incyte Corporation's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| INCY | VTV | |
|---|---|---|
Market Cap | $22.85B | $262.40B |
Volume | 1,927,029 | 3,293,281 |
Sector | Health | — |
52-Week High | $129.93 | $227.51 |
52-Week Low | $83.80 | $182.86 |
Typical Hold Time | 33 Days | 142 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
VTV trades at $219.63, up 0.65% with a bearish technical signal despite bullish moving averages. The ETF shows institutional accumulation with recent purchases by QRG Capital and Blue Edge Capital. Value strategies are gaining attention as VTV outperforms growth counterparts in 2026, offering a 2.3% dividend yield and low 0.03% expense ratio.
VTV presents a defensive value play amid market rotation from growth stocks, with strong institutional support and dividend appeal. Risks include prolonged underperformance versus broad market indices and sensitivity to interest rate changes. The current technical setup suggests cautious near-term momentum with key support at $216.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
